dorzolamide Side Effects
Also known as: Trusopt
Analysis of 7,422 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
7,422
Death-Related
381
5.1% of reports
Hospitalizations
1,356
18.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 381 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 215 |
| PNEUMONIA | 23 |
| RENAL FAILURE | 19 |
| ASTHENIA | 18 |
| RESPIRATORY FAILURE | 17 |
| FALL | 16 |
| OFF LABEL USE | 16 |
| FATIGUE | 15 |
| CHRONIC KIDNEY DISEASE | 13 |
| DYSPNOEA | 13 |
| CONFUSIONAL STATE | 11 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 10 |
| DIZZINESS | 10 |
| GASTROINTESTINAL HAEMORRHAGE | 10 |
| HAEMORRHAGE INTRACRANIAL | 10 |
| SEPSIS | 10 |
| TOXIC EPIDERMAL NECROLYSIS | 10 |
| VOMITING | 10 |
| WEIGHT DECREASED | 10 |
| DECREASED APPETITE | 9 |
Reactions in Hospitalization Reports
Top reactions in 1,356 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 103 |
| PNEUMONIA | 91 |
| OFF LABEL USE | 89 |
| DYSPNOEA | 83 |
| FATIGUE | 75 |
| ACUTE KIDNEY INJURY | 74 |
| DIARRHOEA | 69 |
| ASTHENIA | 65 |
| DIZZINESS | 64 |
| PAIN | 64 |
| DEHYDRATION | 59 |
| DRUG INEFFECTIVE | 54 |
| WEIGHT DECREASED | 54 |
| CONSTIPATION | 53 |
| CONFUSIONAL STATE | 51 |
| NAUSEA | 49 |
| VOMITING | 48 |
| HEADACHE | 47 |
| MALAISE | 40 |
| URINARY TRACT INFECTION | 40 |
Nearby — Related Medications
What the FAERS Data Reveals About dorzolamide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 7,422 voluntary reports linked to dorzolamide and its brand equivalents (Trusopt), spanning 2004 through 2025. Of those, 381 (5.1%) listed death as an outcome and 1,356 (18.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 55% were female and 45% male; age distribution skews toward 75+, with 1,776 reports in that bracket. The single most reported reaction is treatment failure with 1,369 submissions, followed by drug ineffective and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.